Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Other Non-Current Liabilities of $3.5 million for Q2 2026, down 69.57% year-over-year from $11.5 million in Q2 2025, and little changed quarter-over-quarter from $3.5 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Other Non-Current Liabilities for 9 consecutive years, with $3.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 69.57% year-over-year to $3.5 million; the TTM figure through Jun 2026 stood at $3.5 million (down 69.57% YoY), while the FY2025 annual figure was $4.0 million, down 65.22% from the prior year.
- Other Non-Current Liabilities held at $3.5 million in Q2 2026 per PHAT's latest filing, from $3.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $11.5 million in Q4 2024 and bottomed at $3.5 million in Q1 2026.
- Historically, Other Non-Current Liabilities has averaged $8.3 million across 5 years, with a median of $7.5 million in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 81.82% — and 2026, when it sank 69.57%.
- Phathom Pharmaceuticals' Other Non-Current Liabilities stood at $7.5 million in 2022, then climbed by 29.33% to $9.7 million in 2023, then gained by 18.56% to $11.5 million in 2024, then sank by 65.22% to $4.0 million in 2025, then retreated by 12.5% to $3.5 million in 2026.
- Business Quant data shows PHAT's Other Non-Current Liabilities at $3.5 million in Q2 2026, $3.5 million in Q1 2026, and $4.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.50 Mn |
| Mar 31, 2026 | 3.50 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Sep 30, 2025 | 11.50 Mn |
| Jun 30, 2025 | 11.50 Mn |
| Mar 31, 2025 | 11.50 Mn |
| Dec 31, 2024 | 11.50 Mn |
| Sep 30, 2024 | 10.75 Mn |
| Jun 30, 2024 | 10.45 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Dec 31, 2023 | 9.70 Mn |
| Sep 30, 2023 | 7.50 Mn |
| Jun 30, 2023 | 7.50 Mn |
| Mar 31, 2023 | 7.50 Mn |
| Dec 31, 2022 | 7.50 Mn |
| Sep 30, 2022 | 7.50 Mn |
| Jun 30, 2022 | 7.50 Mn |
| Mar 31, 2022 | 7.50 Mn |
| Dec 31, 2021 | 7.50 Mn |
| Sep 30, 2021 | 7.50 Mn |